Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2

Robert Allaway, Steve P. Angus, Roberta L. Beauchamp, Jaishri O. Blakeley, Marga Bott, Sarah S. Burns, Annemarie Carlstedt, Long Sheng Chang, Xin Chen, D. Wade Clapp, Patrick A. DeSouza, Serkan Erdin, Cristina Fernandez-Valle, Justin Guinney, James F. Gusella, Stephen J. Haggarty, Gary L. Johnson, Salvatore La Rosa, Helen Morrison, Alejandra M. PetrilliScott R. Plotkin, Abhishek Pratap, Vijaya Ramesh, Noah Sciaky, Anat Stemmer-Rachamimov, Tim J. Stuhlmiller, Michael E. Talkowski, D. Bradley Welling, Charles W. Yates, Jon S. Zawistowski, Wen Ning Zhao

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Neurofibromatosis 2 (NF2) is a rare tumor suppressor syndrome that manifests with multiple schwannomas and meningiomas. There are no effective drug therapies for these benign tumors and conventional therapies have limited efficacy. Various model systems have been created and several drug targets have been implicated in NF2-driven tumorigenesis based on known effects of the absence of merlin, the product of the NF2 gene. We tested priority compounds based on known biology with traditional dose-concentration studies in meningioma and schwann cell systems. Concurrently, we studied functional kinome and gene expression in these cells pre- and post-treatment to determine merlin deficient molecular phenotypes. Cell viability results showed that three agents (GSK2126458, Panobinostat, CUDC-907) had the greatest activity across schwannoma and meningioma cell systems, but merlin status did not significantly influence response. In vivo, drug effect was tumor specific with meningioma, but not schwannoma, showing response to GSK2126458 and Panobinostat. In culture, changes in both the transcriptome and kinome in response to treatment clustered predominantly based on tumor type. However, there were differences in both gene expression and functional kinome at baseline between meningioma and schwannoma cell systems that may form the basis for future selective therapies. This work has created an openly accessible resource (www.synapse.org/SynodosNF2) of fully characterized isogenic schwannoma and meningioma cell systems as well as a rich data source of kinome and transcriptome data from these assay systems before and after treatment that enables single and combination drug discovery based on molecular phenotype.

Original languageEnglish (US)
Article numbere0197350
JournalPloS one
Volume13
Issue number6
DOIs
StatePublished - Jun 2018

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2'. Together they form a unique fingerprint.

Cite this